Regeneron’s Q2 earnings beat expectations

By: Miguel A. Rodriguez

09:45, 14 September 2020

Developing a Coronavirus vaccine has been tremendously beneficial to Regeneron

After Bayer posted its Q2 earnings yesterday, it was the turn of another pharmaceutical company to do the same. The US-based biotechnology company, Regeneron, posted better-than-expected figures.

During the past quarter, the company's net income rose to $897.3 million, or $7.61 per share. It is almost a nine-fold increase from last year's $193.1 million or $1.68/share.

Regeneron’s revenue increased to $1.95 billion from a previous $1.58 billion. It topped the $1.73 billion consensus. The increase in revenue and stock price was due to the collaboration with Sanofi on developing a COVID-19 vaccine. So far, the vaccine looks promising, as it "almost completely blocks establishment of virus infection," when tested on animals, especially on “mice who have been genetically modified to have a human immune system.” The vaccine is currently in clinical trials on humans, and the results are expected to be published later this summer.

After the report, Regeneron's shares were close to a record high, as they ran up 3.2%. Since the beginning of the year, stocks jumped 72.7%, while USA500 added 2.3%.

News, news, news! Read the latest on!


Share this article

This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.